Immunotherapies are currently the most rapidly growing drug class and have a major impact in the oncology field. While these approaches have demonstrated impressive results for some patients, important challenges still need to be overcome. Among these, defining valuable and adapted combination protocols, predicting responders to therapies through biomarkers, follow-up or overcoming resistance development to current immunotherapies are major goals to achieve.
The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.
In this free webinar, Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Next, Professor Fabrice Barlesi, Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, will focus on the choice of relevant immune-related biomarkers to be tested in order to predict and overcome resistance to treatments in patients suffering from lung cancer. The Pioneer Project, supported by the French Research Agency, will illustrate this topic.
This webinar will also include a brief overview of a powerful immuno-oncology platform that can provide meaningful and actionable data through biomarker testing.
Jérôme Galon, PhD, Director, Inserm UMRS1138, Cordeliers Research Center, Paris, France
Jérôme Galon is the director at INSERM (French NIH) and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is also associate director and co-founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC), co-founder of HalioDx company and the chairman of its scientific council. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture. He pioneered Immunoscore and is the principal investigator of the Worldwide Immunoscore Consortium. His contributions have been recognized with numerous awards, including the William B. Coley Award, USA.
Fabrice Barlesi, MD, PhD, Head of Multidisciplinary Oncology and Therapeutic Innovations, APHM, Coordinator of the Center of Early Phase Cancer Trials of Marseille CLIP2, Professor of Medicine, Aix-Marseille University
Professor Fabrice Barlesi is the head of the multidisciplinary oncology and therapeutic innovations department at Aix Marseille University and coordinator of the Early-Phase Cancer Trials Center (Phase I unit). He is an expert in innovative clinical approaches to pulmonary cancers. He is also responsible for organizing master courses in Lung Cancer Molecular Biology in Marseille Medical University (AMU/AP-HM) and the PIONeeR project, which constitutes a clear illustration of progresses and perspectives in the field.
Who Should Attend?
This webinar will appeal to individuals with the following or related job titles:
- Translational Research / Cancer Research Scientists
- Directors of Immuno-Oncology Programs / Biomarker sciences / Companion Diagnostics / Profiling
- Clinical Trial Managers / Directors / VP
Working in the following research areas:
- Biomarker discovery
- Clinical Trial
What You Will Learn
Attendees will gain insights into:
- How modulation of immune status of tumors during immunotherapies fights cancer cells and the associated mechanisms of action
- Why gaining insights in the immune contexture of tumors at baseline and in the course of clinical trials for immunotherapies is crucial for predicting response to treatment and for deciphering mode of action of resistance to treatments
- How biomarker evaluation can impact immunotherapy drug development
The Immune Response to Cancer Diagnostics
HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Beside diagnostic activities, HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies.
Immunogram ® is a modular platform allowing a comprehensive immunoprofiling of the tumors to be integrated into the preclinical and clinical drug developement processes.
HalioDx has an experienced team of more than 165 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US. For more information, please visit our websites www.haliodx.com and www.immunoscore-colon.com and follow the company on Twitter @HalioDx.